Tag
National data show that Comprehensive Stroke Center status and trial participation independently predict reported stroke rates after TAVR, highlighting potential ascertainment bias affecting hospital performance metrics.
The NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding risk
In low-risk severe aortic stenosis patients, both TAVR and SAVR provide sustained health status improvements over seven years, with TAVR offering faster early recovery but similar long-term health outcomes.
An evidence-based review of the 7-year durability of transcatheter versus surgical aortic bioprosthetic valves in low-risk severe aortic stenosis patients, highlighting comparable long-term structural performance and need for reintervention
The PARTNER 2A 10-year data show higher mortality and reintervention with balloon-expandable SAPIEN XT TAVR versus surgery in intermediate-risk patients, driven mainly by transthoracic access. Contemporary 10-year SAPIEN 3 data, however, su
The EVOLVED trial reveals that higher myocardial fibrosis burden associates with adverse events in asymptomatic severe aortic stenosis patients, yet early intervention benefits appear nuanced—showing promise for reducing hospitalizations in
The 3-year analysis of the LYTEN trial reveals that self-expanding valves (SEV) significantly outperform balloon-expandable valves (BEV) in hemodynamic metrics for valve-in-valve TAVR in patients with small surgical bioprostheses, although
A 10-year multicenter study highlights that cardiac structural complications (CSCs) affect 2.1% of TAVR recipients. With a 35% 30-day mortality rate and no decline in incidence over a decade, these events remain a formidable challenge for i
A nationwide Swedish registry analysis demonstrates that routine PCI before TAVR for significant coronary artery disease does not improve survival or reduce urgent revascularization, but significantly increases bleeding risk while reducing
Seven-year data from the PARTNER 3 trial demonstrate that TAVR remains noninferior to surgical aortic-valve replacement in low-risk patients, with comparable rates of death, stroke, and valve durability, supporting TAVR as a sustained alter
Three-year results from the NOTION-2 trial show comparable clinical outcomes between TAVR and SAVR in younger, low-risk patients. However, higher event rates in the bicuspid subgroup suggest a need for caution and individualized procedural
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
The prospective Pioneer Trial demonstrates that a novel self-expanding TAVR device achieves 99.1% technical success and low mortality (2.7%) at one year for high-risk patients with pure aortic regurgitation, providing a safe, hemodynamicall
The LANDMARK trial reports that the novel Myval balloon-expandable transcatheter heart valve is clinically noninferior to contemporary SAPIEN and Evolut series at one year, offering comparable safety, hemodynamic performance, and quality-of
A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedu
New-onset right bundle branch block after TAVR is rare but carries a high risk of requiring permanent pacing within one week.
One-fourth of TAVR patients receive prophylactic pacemakers, but most have minimal pacing needs at 30 days.
A prospective multicenter study confirms that a prespecified algorithm for conduction disturbance management after TAVR is safe, with low sudden cardiac death risk but persistent high pacemaker rates.
Prospective cohort study reveals AV nodal versus infranodal conduction patterns underpinning timing of heart block after TAVR.
A life cycle assessment found SAVR produces roughly double the carbon footprint of transcatheter aortic valve replacement (TAVR), with postoperative ICU and ward care as the main drivers. Results highlight opportunities to decarbonize cardi
